[go: up one dir, main page]

WO2012033236A1 - Lignée cellulaire mdck adaptée pour culture sans sérum et culture en suspension, et procédé pour préparer des virus pour vaccin utilisant des cellules de celle-ci - Google Patents

Lignée cellulaire mdck adaptée pour culture sans sérum et culture en suspension, et procédé pour préparer des virus pour vaccin utilisant des cellules de celle-ci Download PDF

Info

Publication number
WO2012033236A1
WO2012033236A1 PCT/KR2010/006041 KR2010006041W WO2012033236A1 WO 2012033236 A1 WO2012033236 A1 WO 2012033236A1 KR 2010006041 W KR2010006041 W KR 2010006041W WO 2012033236 A1 WO2012033236 A1 WO 2012033236A1
Authority
WO
WIPO (PCT)
Prior art keywords
virus
mdck
culture
cells
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2010/006041
Other languages
English (en)
Korean (ko)
Inventor
박용욱
이건세
이봉용
박만훈
김훈
김윤희
이수진
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SK Chemicals Co Ltd
Original Assignee
SK Chemicals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SK Chemicals Co Ltd filed Critical SK Chemicals Co Ltd
Priority to PCT/KR2010/006041 priority Critical patent/WO2012033236A1/fr
Priority to KR1020110085902A priority patent/KR20120024464A/ko
Priority to SM20180572T priority patent/SMT201800572T1/it
Priority to CN2011800429238A priority patent/CN103154238A/zh
Priority to PL11823761T priority patent/PL2614140T3/pl
Priority to AU2011299761A priority patent/AU2011299761B2/en
Priority to TR2018/15631T priority patent/TR201815631T4/tr
Priority to LTEP11823761.9T priority patent/LT2614140T/lt
Priority to SI201131565T priority patent/SI2614140T1/sl
Priority to JP2013527024A priority patent/JP6067560B2/ja
Priority to HRP20181422TT priority patent/HRP20181422T1/hr
Priority to PCT/KR2011/006589 priority patent/WO2012033328A2/fr
Priority to RS20181032A priority patent/RS57656B1/sr
Priority to DK11823761.9T priority patent/DK2614140T3/en
Priority to EP11823761.9A priority patent/EP2614140B8/fr
Priority to CN201510201640.3A priority patent/CN104862267B/zh
Priority to ES11823761.9T priority patent/ES2695044T3/es
Priority to HUE11823761A priority patent/HUE040534T2/hu
Priority to BR112013005298-8A priority patent/BR112013005298A2/pt
Priority to PT11823761T priority patent/PT2614140T/pt
Publication of WO2012033236A1 publication Critical patent/WO2012033236A1/fr
Priority to US13/785,757 priority patent/US20130183741A1/en
Anticipated expiration legal-status Critical
Priority to KR1020150063976A priority patent/KR101577745B1/ko
Priority to US14/711,489 priority patent/US9447383B2/en
Priority to CY181101058T priority patent/CY1120911T1/el
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0684—Cells of the urinary tract or kidneys
    • C12N5/0686—Kidney cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16151—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16151—Methods of production or purification of viral material
    • C12N2760/16152—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16171—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16251—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16251—Methods of production or purification of viral material
    • C12N2760/16252—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16271—Demonstrated in vivo effect
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La présente invention concerne une lignée cellulaire MDCK qui est dérivée d'une cellule MDCK déposée sous la forme d'une lignée cellulaire ATCC CCL-34 et peut être cultivée sans sérum et peut être cultivée en suspension, et de préférence, les lignées cellulaires MDCK S1023, MDCK S10234, et MDCK S3851. De plus, la présente invention concerne un procédé de culture pour cultiver la cellule MDCK, et un procédé pour préparer des virus pour des vaccins utilisant la cellule MDCK.
PCT/KR2010/006041 2010-09-06 2010-09-06 Lignée cellulaire mdck adaptée pour culture sans sérum et culture en suspension, et procédé pour préparer des virus pour vaccin utilisant des cellules de celle-ci Ceased WO2012033236A1 (fr)

Priority Applications (24)

Application Number Priority Date Filing Date Title
PCT/KR2010/006041 WO2012033236A1 (fr) 2010-09-06 2010-09-06 Lignée cellulaire mdck adaptée pour culture sans sérum et culture en suspension, et procédé pour préparer des virus pour vaccin utilisant des cellules de celle-ci
KR1020110085902A KR20120024464A (ko) 2010-09-06 2011-08-26 무혈청 배양 및 부유 배양에 적응된 ｍｄｃｋ 세포주 및 상기 세포를 사용하여 백신용 바이러스를 제조하는 방법
DK11823761.9T DK2614140T3 (en) 2010-09-06 2011-09-06 MDCK DERIVATIVE CELL LINES ADAPTED TO SERUM-FREE CULTURE AND SUSPENSION CULTURE AND PROCEDURE FOR PREPARING VACCINE VIRUS USING THE CELLS
CN201510201640.3A CN104862267B (zh) 2010-09-06 2011-09-06 适应于无血清培养和悬浮培养的mdck来源的细胞系与利用该细胞制备疫苗病毒的方法
PL11823761T PL2614140T3 (pl) 2010-09-06 2011-09-06 Linie komórkowe pochodzące z MDCK zaadoptowane do hodowli wolnej od surowicy i hodowli zawiesinowej oraz sposób wytwarzania wirusa szczepionkowego z zastosowaniem tych komórek
AU2011299761A AU2011299761B2 (en) 2010-09-06 2011-09-06 MDCK-derived cell lines adapted to serum-free culture and suspension culture and method for preparing vaccine virus using the cells
TR2018/15631T TR201815631T4 (tr) 2010-09-06 2011-09-06 Serumsuz kültüre ve süspansiyon kültürüne uyarlanan mdck türevi hücre hatları ve bu hücreleri kullanarak aşı virüsü hazırlamak için yöntem.
LTEP11823761.9T LT2614140T (lt) 2010-09-06 2011-09-06 Mdck išvestos ląstelių linijos, adaptuotos auginimui terpėje be serumo, auginimas suspensijoje ir vakcinos viruso paruošimo būdas, naudojant ląsteles
SI201131565T SI2614140T1 (sl) 2010-09-06 2011-09-06 Celične linije pridobljene iz MDCK prilagojene kulturi brez seruma in kulturi suspenzije in postopek priprave cepiva proti virusu z uporabo teh celic
JP2013527024A JP6067560B2 (ja) 2010-09-06 2011-09-06 無血清培養及び浮遊培養に適応されたｍｄｃｋ細胞株及び前記細胞を使用してワクチン用ウイルスを製造する方法
HRP20181422TT HRP20181422T1 (hr) 2010-09-06 2011-09-06 Mdck-derivirane stanične linije prilagođene kulturi bez seruma i suspenzijskoj kulturi te postupak proizvodnje virusa cjepiva koristeći navedene stanice
PCT/KR2011/006589 WO2012033328A2 (fr) 2010-09-06 2011-09-06 Lignées cellulaires dérivées de mdck adaptées à la culture sans sérum et à la culture en suspension et procédé de préparation d'un virus de la vaccine utilisant lesdites cellules
RS20181032A RS57656B1 (sr) 2010-09-06 2011-09-06 Mdck-izvedene ćelijske linije prilagođene kulturi bez seruma i suspenzijskoj kulturi i postupak proizvodnje virusne vakcine koristeći navedene ćelije
SM20180572T SMT201800572T1 (it) 2010-09-06 2011-09-06 Linee cellulari derivate da mdck adattate a coltura priva di siero e a coltura in sospensione e procedimento per la preparazione di un virus vaccinale utilizzando tali cellule
EP11823761.9A EP2614140B8 (fr) 2010-09-06 2011-09-06 Lignées cellulaires dérivées de mdck adaptées à la culture sans sérum et à la culture en suspension et procédé de préparation d'un virus de la vaccine utilisant lesdites cellules
CN2011800429238A CN103154238A (zh) 2010-09-06 2011-09-06 适应于无血清培养和悬浮培养的mdck来源的细胞系与利用该细胞制备疫苗病毒的方法
ES11823761.9T ES2695044T3 (es) 2010-09-06 2011-09-06 Líneas celulares derivadas de MDCK adaptadas a un cultivo exento de suero y a un cultivo en suspensión, y procedimiento para la preparación de un virus para una vacuna usando las células
HUE11823761A HUE040534T2 (hu) 2010-09-06 2011-09-06 Szérummentes tenyésztéshez és szuszpenziós tenyésztéshez adaptált MDCK-eredetû sejtvonalak és eljárás oltóanyagvírus elõállítására a sejtek alkalmazásával
BR112013005298-8A BR112013005298A2 (pt) 2010-09-06 2011-09-06 Linhagem celular derivada de rim canino de madin-darby (mdck), método para produzir um vírus vaccinia usando a linhagem celular derivada de mdck, método para produzir um vírus influenza a partir de uma cultura de célula, vírus ou antígeno de vírus e método para preparar uma linhagem celular derivada de mdck
PT11823761T PT2614140T (pt) 2010-09-06 2011-09-06 Linhagens celulares derivadas de mdck adaptadas para cultura em meio de cultura isento de soro e cultura em suspensão e método para preparação de um vírus vacínico com a utilização das células
US13/785,757 US20130183741A1 (en) 2010-09-06 2013-03-05 Mdck-derived cell lines adapted to serum-free culture and suspension culture and method for preparing vaccine virus using the cells
KR1020150063976A KR101577745B1 (ko) 2010-09-06 2015-05-07 무혈청 배양 및 부유 배양에 적응된 ｍｄｃｋ 세포주 및 상기 세포를 사용하여 백신용 바이러스를 제조하는 방법
US14/711,489 US9447383B2 (en) 2010-09-06 2015-05-13 MDCK-derived cell lines adapted to serum-free culture and suspension culture and method for preparing vaccine virus using the cells
CY181101058T CY1120911T1 (el) 2010-09-06 2018-10-16 Παραγομενες απο mdck κυτταρικες σειρες προσαρμοσμενες σε απαλλαγμενη απο ορο καλλιεργεια και καλλιεργεια εναιωρηματος και μεθοδος για παρασκευη ιου εμβολιου χρησιμοποιωντας τα κυτταρα

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/KR2010/006041 WO2012033236A1 (fr) 2010-09-06 2010-09-06 Lignée cellulaire mdck adaptée pour culture sans sérum et culture en suspension, et procédé pour préparer des virus pour vaccin utilisant des cellules de celle-ci

Publications (1)

Publication Number Publication Date
WO2012033236A1 true WO2012033236A1 (fr) 2012-03-15

Family

ID=45810820

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/KR2010/006041 Ceased WO2012033236A1 (fr) 2010-09-06 2010-09-06 Lignée cellulaire mdck adaptée pour culture sans sérum et culture en suspension, et procédé pour préparer des virus pour vaccin utilisant des cellules de celle-ci
PCT/KR2011/006589 Ceased WO2012033328A2 (fr) 2010-09-06 2011-09-06 Lignées cellulaires dérivées de mdck adaptées à la culture sans sérum et à la culture en suspension et procédé de préparation d'un virus de la vaccine utilisant lesdites cellules

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/KR2011/006589 Ceased WO2012033328A2 (fr) 2010-09-06 2011-09-06 Lignées cellulaires dérivées de mdck adaptées à la culture sans sérum et à la culture en suspension et procédé de préparation d'un virus de la vaccine utilisant lesdites cellules

Country Status (20)

Country Link
US (2) US20130183741A1 (fr)
EP (1) EP2614140B8 (fr)
JP (1) JP6067560B2 (fr)
KR (2) KR20120024464A (fr)
CN (2) CN103154238A (fr)
AU (1) AU2011299761B2 (fr)
BR (1) BR112013005298A2 (fr)
CY (1) CY1120911T1 (fr)
DK (1) DK2614140T3 (fr)
ES (1) ES2695044T3 (fr)
HR (1) HRP20181422T1 (fr)
HU (1) HUE040534T2 (fr)
LT (1) LT2614140T (fr)
PL (1) PL2614140T3 (fr)
PT (1) PT2614140T (fr)
RS (1) RS57656B1 (fr)
SI (1) SI2614140T1 (fr)
SM (1) SMT201800572T1 (fr)
TR (1) TR201815631T4 (fr)
WO (2) WO2012033236A1 (fr)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2614140A4 (fr) * 2010-09-06 2014-03-05 Sk Chemicals Co Ltd Lignées cellulaires dérivées de mdck adaptées à la culture sans sérum et à la culture en suspension et procédé de préparation d'un virus de la vaccine utilisant lesdites cellules
CN104726392A (zh) * 2013-12-18 2015-06-24 普莱柯生物工程股份有限公司 一种制备无血清培养的悬浮哺乳动物细胞系的方法、及其制备的细胞系和应用
CN105861422A (zh) * 2016-06-24 2016-08-17 广东温氏大华农生物科技有限公司 一种适应无血清全悬浮培养的mdck细胞系的制备方法及通过该制备方法获得的mdck细胞系
CN112195148A (zh) * 2020-08-17 2021-01-08 上海生物制品研究所有限责任公司 无血清悬浮适应的mdck细胞及其在制备流感病毒疫苗中的应用
CN112410305A (zh) * 2020-11-26 2021-02-26 中国医学科学院病原生物学研究所 一种高产的流感病毒制备体系及制备方法

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2010557B1 (fr) 2006-03-31 2014-02-26 Wisconsin Alumni Research Foundation Virus de la grippe recombinants à haut titre pour vaccins
US9474798B2 (en) 2007-06-18 2016-10-25 Wisconsin Alumni Research Foundation Influenza M2 protein mutant viruses as live influenza attenuated vaccines
EP2493912B1 (fr) 2009-10-26 2020-07-29 Wisconsin Alumni Research Foundation Virus recombinants de la grippe de titre élevé à réplication améliorée dans les cellules vero
US10130697B2 (en) 2010-03-23 2018-11-20 Wisconsin Alumni Research Foundation (Warf) Vaccines comprising mutant attenuated influenza viruses
WO2013032942A1 (fr) 2011-08-26 2013-03-07 Yoshihiro Kawaoka Virus de la grippe ayant un segment génique pb2 mutant en tant que vaccins vivants atténués
JP6152535B2 (ja) * 2012-04-16 2017-06-28 公益財団法人ヒューマンサイエンス振興財団 細胞培養組成物及びインフルエンザウイルスの生産方法
CN104059873B (zh) * 2013-03-20 2016-09-28 上海生物制品研究所有限责任公司 用于扩增流感病毒的非致瘤性mdck细胞系及其筛选方法
KR101370512B1 (ko) * 2013-06-07 2014-03-06 재단법인 목암생명공학연구소 무단백 배지에서 부유 배양되는 mdck 유래 세포주 및 상기 세포주를 이용하여 바이러스를 증식시키는 방법
EP3022296B1 (fr) 2013-07-15 2022-12-28 Wisconsin Alumni Research Foundation Virus influenza recombinés à titre élevé avec augmentation de la réplication dans les oeufs ou les cellules de la lignée vero ou mdck
US10053671B2 (en) 2014-06-20 2018-08-21 Wisconsin Alumni Research Foundation (Warf) Mutations that confer genetic stability to additional genes in influenza viruses
US10633422B2 (en) 2015-06-01 2020-04-28 Wisconsin Alumni Research Foundation (Warf) Influenza virus replication by inhibiting microRNA lec7C binding to influenza viral cRNA and mRNA
US9890363B2 (en) 2015-07-06 2018-02-13 Wisconsin Alumni Research Foundation (Warf) Influenza virus replication for vaccine development
US10786564B2 (en) * 2015-10-30 2020-09-29 National Health Research Institutes MDCK suspension cell lines in serum-free, chemically-defined media for vaccine production
CA3014435C (fr) 2016-02-19 2023-04-18 Wisconsin Alumni Research Foundation (Warf) Replication amelioree du virus de la grippe b pour l'elaboration de vaccin
CN107460156B (zh) * 2016-06-03 2022-03-11 兆丰华生物科技(南京)有限公司北京生物医药科技中心 无血清全悬浮mdck细胞株及其在生产流感病毒中的应用
EP3299454A1 (fr) * 2016-09-21 2018-03-28 Deutsches Krebsforschungszentrum Procédé optimisé pour une production à grande échelle de parvovirus h-1 dans un milieu essentiellement sans sérum
CN106884003A (zh) * 2017-01-22 2017-06-23 西北民族大学 无成瘤性mdck细胞克隆株
CN106801031A (zh) * 2017-01-22 2017-06-06 西北民族大学 无成瘤性mdck细胞克隆株
KR101831284B1 (ko) * 2017-06-26 2018-02-22 에스케이케미칼 주식회사 무혈청 배지에서 부유배양 되는 Vero 세포주 및 상기 세포를 사용하여 백신용 바이러스를 제조하는 방법
KR102453351B1 (ko) 2017-07-05 2022-10-07 에스케이바이오사이언스(주) 인플루엔자 백신용 바이러스 씨드 스톡의 제조 방법
JP2021500891A (ja) 2017-10-25 2021-01-14 ウィスコンシン アルムニ リサーチ ファンデイション 卵における複製のための安定化されたｈａを有する組換えインフルエンザウイルス
CN108277199B (zh) * 2018-01-17 2021-06-25 武汉生物制品研究所有限责任公司 广谱低致瘤性mdck细胞系及其应用
US12343390B2 (en) 2018-08-07 2025-07-01 Wisconsin Alumni Research Foundation (Warf) Recombinant biologically contained filovirus vaccine
JP7655849B2 (ja) 2018-08-20 2025-04-02 ウィスコンシン アルムニ リサーチ ファンデイション ヘマグルチニン（ｈａ）タンパク質内の非ドミナントエピトープに対する免疫応答を誘起するためのベクター
WO2020167432A2 (fr) 2019-01-23 2020-08-20 Yoshihiro Kawaoka Mutations conférant une stabilité génétique à des gènes supplémentaires dans des virus de la grippe
CN113874496A (zh) 2019-02-08 2021-12-31 威斯康星校友研究基金会(Warf) 人源化细胞系
CN109852579A (zh) * 2019-03-27 2019-06-07 西北民族大学 无血清悬浮培养型mdck细胞株及其应用
CN109852580A (zh) * 2019-03-27 2019-06-07 西北民族大学 无血清悬浮培养型mdck细胞株及其应用
US11390649B2 (en) 2019-05-01 2022-07-19 Wisconsin Alumni Research Foundation (Warf) Influenza virus replication for vaccine development
JP7627911B2 (ja) 2019-08-27 2025-02-07 ウィスコンシン アルムニ リサーチ ファンデイション 卵内複製のための安定化されたｈａを持つ組換えインフルエンザウイルス
CN110669722A (zh) * 2019-10-23 2020-01-10 长春生物制品研究所有限责任公司 一种用于mdck细胞的无血清全悬浮驯化方法
KR102696955B1 (ko) * 2019-11-27 2024-08-19 에스케이바이오사이언스(주) 무혈청 배지에서 부유배양이 가능한 신규한 Vero 세포주, 이의 제조 방법 및 상기 신규 세포주를 이용한 백신용 바이러스 제조 방법
US11739303B2 (en) 2020-01-24 2023-08-29 Wisconsin Alumni Research Foundation (Warf) Recombinant influenza viruses with stabilized NA
US12290562B2 (en) 2020-03-25 2025-05-06 Wisconsin Alumni Research Foundation (Warf) Recombinant multivalent influenza viruses
EP4144753A4 (fr) 2020-04-29 2024-12-25 SK Bioscience Co., Ltd. Procédé de production du virus de la grippe à l'aide d'un système de procédé de culture jetable, et test permettant de vérifier rapidement les conditions de purification d'antigène du virus de la grippe
KR102444684B1 (ko) * 2020-04-29 2022-09-16 에스케이바이오사이언스(주) 일회용 배양 공정 시스템을 이용한 인플루엔자 바이러스 생산 방법

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6825036B2 (en) * 2000-03-03 2004-11-30 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Cell usable in serum-free culture and suspension culture and process for producing virus for vaccine by using the cell

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10144906B4 (de) * 2001-09-12 2013-11-28 Novartis Vaccines And Diagnostics Gmbh Verfahren zur großtechnischen Herstellung von Impfstoffen
KR101260084B1 (ko) * 2004-12-23 2013-05-03 메디뮨 엘엘씨 바이러스의 증식을 위한 비종양형성성 ｍｄｃｋ 세포주
ES3031467T3 (en) 2006-09-11 2025-07-09 Seqirus Uk Ltd Making influenza virus vaccines without using eggs
EP2344634A4 (fr) * 2008-09-24 2012-08-29 Medimmune Llc Procédés de culture de cellules, et de propagation et de purification de virus
WO2012033236A1 (fr) * 2010-09-06 2012-03-15 에스케이케미칼 주식회사 Lignée cellulaire mdck adaptée pour culture sans sérum et culture en suspension, et procédé pour préparer des virus pour vaccin utilisant des cellules de celle-ci

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6825036B2 (en) * 2000-03-03 2004-11-30 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Cell usable in serum-free culture and suspension culture and process for producing virus for vaccine by using the cell

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CHU, C. ET AL.: "Conversion of MDCK cell line to suspension culture by transfecting with human siat7e gene and its application for influenza virus production", PNAS, vol. 106, no. 35, 1 September 2009 (2009-09-01), pages 14802 - 14807 *
GEORGE, M. ET AL.: "Production of Cell Culture (MDCK) Derived Live Attenuated Influenza Vaccine (LAFV) in a Fully Disposable Platform Process", BIOTECHNOLOGY AND BIOENGINEERING, vol. 106, no. 6, 15 August 2010 (2010-08-15), pages 906 - 917 *
SAFC BIOSCIENCES: "Suspension MDCK Cell Culture in EX-CELL (TM) MDCK Serum- Free Medium", TECHNICAL BULLETIN, 31 March 2006 (2006-03-31) *

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2614140A4 (fr) * 2010-09-06 2014-03-05 Sk Chemicals Co Ltd Lignées cellulaires dérivées de mdck adaptées à la culture sans sérum et à la culture en suspension et procédé de préparation d'un virus de la vaccine utilisant lesdites cellules
CN104726392A (zh) * 2013-12-18 2015-06-24 普莱柯生物工程股份有限公司 一种制备无血清培养的悬浮哺乳动物细胞系的方法、及其制备的细胞系和应用
CN105861422A (zh) * 2016-06-24 2016-08-17 广东温氏大华农生物科技有限公司 一种适应无血清全悬浮培养的mdck细胞系的制备方法及通过该制备方法获得的mdck细胞系
CN105861422B (zh) * 2016-06-24 2019-05-24 肇庆大华农生物药品有限公司 一种适应无血清全悬浮培养的mdck细胞系的制备方法及通过该制备方法获得的mdck细胞系
CN112195148A (zh) * 2020-08-17 2021-01-08 上海生物制品研究所有限责任公司 无血清悬浮适应的mdck细胞及其在制备流感病毒疫苗中的应用
CN112195148B (zh) * 2020-08-17 2023-01-03 上海生物制品研究所有限责任公司 无血清悬浮适应的mdck细胞及其在制备流感病毒疫苗中的应用
CN112410305A (zh) * 2020-11-26 2021-02-26 中国医学科学院病原生物学研究所 一种高产的流感病毒制备体系及制备方法

Also Published As

Publication number Publication date
US20130183741A1 (en) 2013-07-18
EP2614140B1 (fr) 2018-08-08
CN104862267A (zh) 2015-08-26
PL2614140T3 (pl) 2019-02-28
DK2614140T3 (en) 2018-10-22
SI2614140T1 (sl) 2018-11-30
LT2614140T (lt) 2018-10-25
CN103154238A (zh) 2013-06-12
ES2695044T3 (es) 2018-12-28
CN104862267B (zh) 2019-07-12
SMT201800572T1 (it) 2019-01-11
HRP20181422T1 (hr) 2018-10-19
EP2614140B8 (fr) 2018-10-17
WO2012033328A3 (fr) 2012-06-28
KR101577745B1 (ko) 2015-12-16
RS57656B1 (sr) 2018-11-30
WO2012033328A2 (fr) 2012-03-15
AU2011299761A1 (en) 2013-03-21
HUE040534T2 (hu) 2019-03-28
US9447383B2 (en) 2016-09-20
CY1120911T1 (el) 2019-12-11
EP2614140A2 (fr) 2013-07-17
AU2011299761B2 (en) 2017-01-05
BR112013005298A2 (pt) 2020-01-07
KR20120024464A (ko) 2012-03-14
US20150247128A1 (en) 2015-09-03
PT2614140T (pt) 2018-11-22
JP2013540431A (ja) 2013-11-07
TR201815631T4 (tr) 2018-11-21
JP6067560B2 (ja) 2017-01-25
EP2614140A4 (fr) 2014-03-05
KR20150056519A (ko) 2015-05-26

Similar Documents

Publication Publication Date Title
WO2012033236A1 (fr) Lignée cellulaire mdck adaptée pour culture sans sérum et culture en suspension, et procédé pour préparer des virus pour vaccin utilisant des cellules de celle-ci
KR100968141B1 (ko) 세포 배양물에서 바이러스의 증식 방법
JP3754088B2 (ja) ウィルス増殖のための不死化細胞系
JP4698112B2 (ja) 無血清培養かつ浮遊培養可能な細胞及び当該細胞を用いたワクチン用ウイルスの製造法
KR100999345B1 (ko) Ｍｄｃｋ 세포 현탁 배양물 중에서 약물 또는 진단제 활성 성분의 생산 방법
WO2019004556A1 (fr) Suspension de lignée de cellules véro cultivée dans un milieu sans sérum et procédé de production de virus vaccinal utilisant ladite suspension
JP6110357B2 (ja) イヌ腎細胞の浮遊培養物においてウイルスを複製する方法
KR101370512B1 (ko) 무단백 배지에서 부유 배양되는 mdck 유래 세포주 및 상기 세포주를 이용하여 바이러스를 증식시키는 방법
CN102526720B (zh) 一种流感病毒疫苗的制备方法
Takemoto et al. Influence of acid polysaccharides on plaque formation by influenza A2 and B viruses
JP7688639B2 (ja) 無血清培地で浮遊培養可能な新規のベロ細胞株、その製造方法、及び該新規細胞株を用いたワクチン用ウイルスの製造方法
CN105408469A (zh) 禽类胚胎细胞的制备
Sekar et al. Comparative Analysis of MEM, RPMI 1640 Media on Rabies Virus Propagation in Vero Cells and Virus Quantification by FAT
SU1518370A1 (ru) Штамм культивируемых клеток кожи и мышц эмбриона человека дл изготовлени диагностических препаратов
CN112251415A (zh) 一种鸡新城疫病毒分离方法
CN118792263A (zh) 以mrc-5细胞制备高滴度狂犬病病毒的方法及应用
CN121006317A (zh) 一种永生化鸡胚肾上皮样细胞及其制备方法和应用
CN112870343A (zh) 一种基于人造新冠病毒孵化细胞的灭活疫苗制备方法
KR20000045065A (ko) 인체 태아 폐조직으로부터 분리된 바이러스 및 생물학적 활성물질 민감성 세포, 그의 제조방법 및 용도
HK1022496B (en) Immortalized cell lines for virus growth

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10857023

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 04.07.13)

122 Ep: pct application non-entry in european phase

Ref document number: 10857023

Country of ref document: EP

Kind code of ref document: A1